Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.79 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.79 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421987 | 0.89 | ADORA2A (1.00) | ADORA2ANUDT1SCN9ADCPSMEN1 | |
| Hydrochloric Acid SCHEMBL27344186 | 0.87 | ADORA2A (0.96) | ADORA2ANUDT1SCN9ADCPSMEN1 | |
| SCHEMBL12281655 | 0.85 | ADORA2A (0.92) | ADORA2ANUDT1SCN9AADORA1DCPS | |
| SCHEMBL17959853 | 0.83 | ADORA2A (0.69) | ADORA2ANUDT1SCN9AADORA1 | |
| SCHEMBL31375930 | 0.82 | ADORA2A (0.53) | ADORA2ANUDT1ADORA1 | |
| SCHEMBL20258996 | 0.79 | ALDH1A1 (0.68) | ADORA2ANUDT1MEN1KMT2AATM | |
| SCHEMBL28925268 | 0.79 | MEN1 (0.68) | ADORA2ANUDT1MEN1KMT2AATM | |
| SCHEMBL3040103 | 0.78 | ADORA2A (0.61) | ADORA2ANUDT1SCN9ADCPS | |
| SCHEMBL23996449 | 0.77 | MEN1 (0.66) | MEN1KMT2AATM | |
| SCHEMBL16436458 | 0.77 | MEN1 (0.66) | MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | ADORA2A 1325/4885NUDT1 917/4885SCN9A 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.